| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5825022 | Clinical Therapeutics | 2015 | 11 Pages |
Abstract
Prasugrel 30 and 60 mg exhibited slightly stronger, more rapid, and sustainable platelet inhibitory effects compared with ticagrelor 180 mg. These differing effects should be considered when determining the efficacy and adverse effects of ticagrelor and prasugrel. ClinicalTrials.gov identifier: NCT01876797 and NCT02075268.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Hae-Sun MD, Mi-Jo MD, PhD, Hee-Youn MD, Yo-Han MD, Eun-Hwa BS, A-Reum MS, Hyun-Jung BS, Kyun-Seop MD, PhD, Hyeong-Seok MD, PhD,